DCPH News and Press, Deciphera Pharmaceuticals Inc. From 01/24/23

– Second-Line GIST Patients with Mutations in KIT Exon 11 + 17/18 Only Demonstrated Substantial Clinical Benefit from QINLOCK ® but Not Sunitinib – – Company Plans to Initiate the INSIGHT Pivotal Phase 3 Clinical Study in the Second Half of 2023 – ...

Deciphera Pharmaceuticals ( NASDAQ: DCPH ) has priced an underwritten public offering of 6,944,445 shares of its common stock at a public offering price of $18.00/share, for expected gross proceeds expected to be ~$125M. Underwriters are granted a 30-day option to purchase up to a...

Deciphera Pharma ( NASDAQ: DCPH ) said it it expects to offer and sell $125M shares of its common stock in an underwritten public offering. Deciphera would grant the underwriters a 30-day option to purchase up to an additional $18.75M of shares of common stock offered in the publi...

– Plans to Initiate Pivotal Phase 3 INSIGHT Study of QINLOCK ® Versus Sunitinib in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only in the Second Half of 2023 Based on ctDNA Analysis from INTRIGUE Study – – Expects to Complete Enrollment...

– Median Progression Free Survival for QINLOCK of 14.2 Months Versus Sunitinib of 1.5 Months; Hazard Ratio of 0.22, nominal p value <0.0001 – – Objective Response Rate of 44.4% for QINLOCK Versus 0% for Sunitinib; nominal p value 0.0001 – – Me...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 9:45 AM PT. A live webcast of the event will be available on the “E...

Summary Shares have lost three quarters of their value over the past three years but logged a 60% gain in the past 12 months. Qinlock sales are steadily growing in 4th line GIST with potential to see off-label use in earlier lines of therapy given favorable tolerability profile. Vis...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 6, 2022 at 10:40 AM ET. A live webcast of the firesid...

Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Jen Larson – Senior Vice President-Finance and Investor Relations Steve Hoerter – President and Chief Executive Officer Dan Mart...

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Deciphera Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation